ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant...
Read More
Meeting Coverage
ESMO: Dual AR/AKT blockade effective in mCRPC with PTEN loss
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. The phase 3...
Read More
ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...
Read More
ESMO: CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
No standard treatment has been defined yet for second- or third-line systemic treatment of...
Read More
ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?
According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...
Read More
ESMO: Immunotherapy Improves Gastric Cancer Outcomes
Addition to chemotherapy may set a new Standard Immunotherapy for patients with high-risk gastric...
Read More
ECTRIMS-ACTRIMS 2020 Late Breaking News: Encore Session, Sept 26th
The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...
Read MorePhysQuiz Answers! ACR Convergence 2020
Thank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do? 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for...
Read More
ESMO Virtual Congress 2020 Around the Corner: All Eyes On Lung Cancer
The ESMO Virtual Congress 2020, September 19-21, will present promising new developments aimed at...
Read MoreESMO 2020: Tumor-Agnostic Data from STARTRK-1 and STARTRK-2
Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of...
Read MoreESMO 2020: Analysis of Long-Term Survivors in the IMpower133 Trial for ES-SCLC
Results from an exploratory analysis of characterization of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomization, in the IMpower133 trial will be presented in a...
Read More
ACTRIMS-ECTRIMS: Thyroid Disorders Don’t Affect MS Control
Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among...
Read More
ACTRIMS-ECTRIMS: Advantages Seen for Ozanimod over Teriflunomide
Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...
Read MoreFinal Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Bevacizumab
final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin® )in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive...
Read More
ACTRIMS-ECTRIMS: Alemtuzumab Slows Brain Atrophy in MS Patients
Benefit observed in patients with or without disease activity Among multiple sclerosis patients...
Read More
MSVirtual2020: Anticipated Efficacy Results from Phase IV MAGNIFY-MS Study
Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined...
Read More
Upcoming MSVirtual2020: Virtual Joint ACTRIMS-ECTRIMS Meeting
MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis...
Read More
ACTRIMS-ECTRIMS: Anticipated Results from ASCLEPIOS Phase III
New efficacy and safety data on ofatumumab (Kesimpta), the first and only self-administered,...
Read More
ACTRIMS-ECTRIMS: Progressive Forms of MS and Disease-Modifying Therapies
Health Union has been accepted to present research, in the form of two poster presentations,...
Read More
ACTRIMS-ECTRIMS: The Potential of Brain-Penetrant BTK Inhibitors
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read More